Results 151 to 160 of about 49,034 (223)

Hormonal management after risk-reducing surgery in BRCA-mutated triple-negative breast cancer survivors. [PDF]

J Cancer Res Clin Oncol
Jörg I, Chronas D.
europepmc   +1 more source

Effects of similarity networks in graph-based multi-omics classification. [PDF]

PLoS One
Siam MBH, Khan MR, Elahe MF, Arman MS, Akter S.   +4 more
europepmc   +1 more source

TRIM59 (Tripartite Motif-Containing 59) Expression in Pan-Cancer and Its Diagnostic and Prognostic Implications in Breast Cancer, Esophageal Cancer, Lung Squamous Cell Carcinoma, and Stomach Adenocarcinoma. [PDF]

Cureus
Attaelmanan GA, Fateh Alrhman MY, Abdelrahman DN, Mohamed T, Elkhidir M, Mohamed RR, Hamad H, Mohamed M, Siddig E, Muzzammil M, Alfaki M.   +10 more
europepmc   +1 more source

Evaluating the impact of the CHANGE initiative on cancer screening referral and uptake in underserved communities in Georgia. [PDF]

Prev Med Rep
Tsai MH, Vernon MM, Carrillo A, Pollard E, Tingen MS.   +4 more
europepmc   +1 more source

Role of SUV39H2 in shaping the malignant phenotype of triple-negative breast cancer. [PDF]

Front Oncol
Wang ZW, Hu S, Chen Y, Lu Y, Li SF, Deng Y, Jiang HT.   +6 more
europepmc   +1 more source

Νovel methylation biomarkers in liquid biopsy and classifying biosignatures for the clinical management of breast cancer. [PDF]

Breast Cancer Res
Panagopoulou M, Papadaki MA, Karaglani M, Theodosiou T, Michaelidou K, Baritaki S, Tsamardinos I, Kakolyris S, Agelaki S, Chatzaki E.   +9 more
europepmc   +1 more source

Bone Metastasis: Molecular Mechanisms, Clinical Management, and Therapeutic Targets. [PDF]

MedComm (2020)
Wen J, Li B, Wang S, Yao Y, Huang Z, Yu D.   +5 more
europepmc   +1 more source

Silencing RPL9 promotes malignant proliferation in breast cancer cells. [PDF]

Int J Immunopathol Pharmacol
Zhu T, Dai J, Li W, Zhang H, Song Y, Zhang D, Liu R, Wang X, Shi Z, Tang H, Zhu X, Liu Y.   +11 more
europepmc   +1 more source

Surgical Timing and Survival in Advanced High-Grade Serous Ovarian Cancer in the PARP Inhibitor Era. [PDF]

Cancers (Basel)
Kanno M, Fusegi A, Miyazaki N, Ozawa R, Netsu S, Aoki Y, Omi M, Nomura H, Yunokawa M, Kanao H.   +9 more
europepmc   +1 more source